Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE
Most relevant news about ROCHE HOLDING LTD.
09/21AbbVie Gets Positive CHMP Opinion for Combination of Venclyxto With Rituximab..
DJ
09/13Roche Works to Fill Sales Gap as Biosimilars Emerge -Reuters
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/13ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Syste..
BU
09/13ROCHE : boss says Brexit and curbs on drug use pose threat to UK science
RE
09/10U.K. Health Regulator Rejects Roche's MS Drug
DJ
09/10ROCHE : faces UK pricing row over multiple sclerosis drug Ocrevus
RE
09/06FDA Extends Review Period for Roche Cancer Treatment License
DJ
09/06GENENTECH : to Present New Data from Its Extensive Lung Cancer Program at the 20..
BU
09/04With drugs pipeline in focus, Bayer considers job cuts
RE
09/04With drugs pipeline in focus, Bayer considers job cuts - source
RE
08/30ROCHE : Positive Phase III Results for Genentech’s HEMLIBRA (emicizumab-kx..
BU
08/29Europe ready to cash in on cheap copies of AbbVie biotech drug
RE
08/28Swiss drugmaker Roche's diagnostics head exits
RE
08/27Affimed Announces Collaboration with Genentech, Shares Rocket After Hours
DJ
More most relevant news
All news about ROCHE HOLDING LTD.
09/21AbbVie Gets Positive CHMP Opinion for Combination of Venclyxto With Rituximab..
DJ
09/13Roche Works to Fill Sales Gap as Biosimilars Emerge -Reuters
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/13ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Syste..
BU
09/13ROCHE : boss says Brexit and curbs on drug use pose threat to UK science
RE
09/10U.K. Health Regulator Rejects Roche's MS Drug
DJ
09/10ROCHE : faces UK pricing row over multiple sclerosis drug Ocrevus
RE
09/06FDA Extends Review Period for Roche Cancer Treatment License
DJ
09/06GENENTECH : to Present New Data from Its Extensive Lung Cancer Program at the 20..
BU
09/04With drugs pipeline in focus, Bayer considers job cuts
RE
More news
Sector news : Pharmaceuticals - NEC
02:06aJ&J UNIT : Esketamine Study Didn't Show Statistical Significance for Primary End..
DJ
09/21JOHNSON & JOHNSON : J&J Unit Agrees To Sell Sterilization Unit for $2.7 Billion
DJ
09/21EMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
09/21Triple Set of EMA Recommendations for Novartis Drugs
DJ
09/21GlaxoSmithKline, Innoviva Get Positive CHMP Opinion on Expanded COPD Indicati..
DJ
09/21ELI LILLY AND : Gets Positive CHMP Opinion for Migraine Drug Emgality
DJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08:26aSTOCKS TO WATCH : Calling Up Animal Spirits 
09/21Key events next week - healthcare 
09/21New opinions from EMA advisor CHMP 
09/20Arvinas Holding Prepares Terms For $100 Million IPO 
09/18Roche launches two NAVIFY clinical decision support apps 
09/17House nixes drug prices in TV ads 
Latest Tweets
03:30pHis name may not be familiar to many Irish football fans, but for the support.. 
02:16pSenseonics $SENS Trading Up 5%  
01:00pFresh from his testimonial, Irish goalkeeper Barry Roche reflects on a career.. 
11:05a'I’ve been here for over 10 years now and everyone here knows how much the cl.. 
09/21Roche : announces CHMP recommendation for EU approval of Venclyxto plus MabTh.. 
More tweets
Qtime:232
Financials (CHF)
Sales 2018 56 475 M
EBIT 2018 19 233 M
Net income 2018 12 946 M
Debt 2018 4 708 M
Yield 2018 3,74%
P/E ratio 2018 15,54
P/E ratio 2019 15,24
EV / Sales 2018 3,67x
EV / Sales 2019 3,52x
Capitalization 203 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 259  CHF
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-4.60%211 501
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
MERCK AND COMPANY25.79%189 092
AMGEN17.94%132 756